Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

被引：8
|
作者：
Shah, Nina [1 ]
Munshi, Nikhil C. [2 ]
Berdeja, Jesus G. [3 ,4 ]
Jagannath, Sundar [5 ]
Finney, Olivia [6 ]
Martin, Nathan [7 ]
Agarwal, Amit [7 ]
Rowe, Everton [7 ]
Campbe, Timothy B. [7 ]
San-Miguel, Jesus F. [8 ]
机构：
[1] UCSF, Med Ctr, San Francisco, CA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Tennessee Oncol, Nashville, TN USA
[4] Sarah Cannon Canc Ctr, Nashville, TN USA
[5] Mt Sinai Med Ctr, New York, NY USA
[6] Bluebird bio, Cambridge, MA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1739
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Campbell, Timothy
    Lee, Abraham
    Patwardhan, Pallavi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
  • [42] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [43] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
    Ayers, Dieter
    Cope, Shannon
    Dhanda, Devender S.
    Towle, Kevin
    Mojebi, Ali
    Delforge, Michel
    Rodriguez-Otero, Paula
    Trudel, Suzanne
    Weisel, Katja
    Zamagni, Elena
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
  • [44] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
    Albert, Oriol
    Ankit, Kansagra
    Yi, Lin
    Jesus, Berdeja
    Nina, Shah
    Ibrahim, Yakoub-Agha
    Hermann, Einsele
    Alessandro, Rambaldi
    Anna, Truppel-Hartmann
    Everton, Rowe
    Julie, Wang
    Amit, Agarwal
    Timothy, Campbell B.
    Sagar, Lonial
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
  • [45] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [46] Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy.
    Rytlewski, Julie
    Fuller, Jaymes
    Mertz, David R.
    Freeman, Ciara
    Manier, Salomon
    Shah, Nina
    Campbell, Timothy Brandon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] HEALTHCARE RESOURCE UTILIZATION AND 2022 COST UPDATE OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN KARMMA
    McGarvey, N.
    Imanak, K.
    Carattini, T.
    Ung, B.
    Campbell, T. B.
    Gitlin, M.
    Patwardhan, P.
    VALUE IN HEALTH, 2023, 26 (06) : S89 - S89
  • [48] Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
    McGarvey, November
    Carattini, Thomas
    Ung, Brian
    Campbell, Timothy B.
    Imanak, Ken
    Patwardhan, Pallavi
    BLOOD, 2022, 140 : 10947 - 10948
  • [49] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
    Jesus, San-Miguel
    Noopur, Raje S.
    David, Siegel
    Sundar, Jagannath
    Sagar, Lonial
    Nikhil, Munshi C.
    Philippe, Moreau
    Hartmut, Goldschmidt
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Huang Liping
    Amit, Agarwal
    Julie, Wang
    Timothy, Campbell B.
    Donna, Reece E.
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
  • [50] Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus
    Moshkovich, Olga
    Braverman, Julia
    Dhanda, Devender S.
    Lanar, Sally
    Miera, Matthew
    Williams, Agnes
    Murphy, Ryan
    Devlen, Jennifer
    Hege, Kristen
    Campbell, Timothy B.
    Munshi, Nikhil C.
    LEUKEMIA RESEARCH, 2022, 120
12345